304 related articles for article (PubMed ID: 30124524)
1. Theratyping in cystic fibrosis.
Crawford KJ; Downey DG
Curr Opin Pulm Med; 2018 Nov; 24(6):612-617. PubMed ID: 30124524
[TBL] [Abstract][Full Text] [Related]
2. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
3. The march towards CFTR modulator access for all people with CF: The end of the beginning.
VanDevanter DR
J Cyst Fibros; 2021 Mar; 20(2):185-187. PubMed ID: 33495080
[No Abstract] [Full Text] [Related]
4. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
5. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential.
Elborn JS; Davies J
Lancet Respir Med; 2017 Sep; 5(9):681-683. PubMed ID: 28853396
[No Abstract] [Full Text] [Related]
7. Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy.
Virant-Young D; Thomas J; Woiderski S; Powers M; Carlier J; McCarty J; Kupchick T; Larder A
J Am Osteopath Assoc; 2015 Sep; 115(9):546-55. PubMed ID: 26322933
[TBL] [Abstract][Full Text] [Related]
8. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
Mayer-Hamblett N; Boyle M; VanDevanter D
Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
[TBL] [Abstract][Full Text] [Related]
9. CFTR modulator therapy in patients with cystic fibrosis and an organ transplant.
Mitchell RM; Jones AM; Barry PJ
Paediatr Respir Rev; 2018 Jun; 27():6-8. PubMed ID: 30158080
[TBL] [Abstract][Full Text] [Related]
10. Genomically-guided therapies: A new era for cystic fibrosis.
Fajac I; Girodon E
Arch Pediatr; 2020 Feb; 27 Suppl 1():eS41-eS44. PubMed ID: 32172937
[TBL] [Abstract][Full Text] [Related]
11. Ion Channel Modulators in Cystic Fibrosis.
Gentzsch M; Mall MA
Chest; 2018 Aug; 154(2):383-393. PubMed ID: 29750923
[TBL] [Abstract][Full Text] [Related]
12. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
Bitonti M; Fritts L; So TY
J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
[TBL] [Abstract][Full Text] [Related]
13. Treating Specific Variants Causing Cystic Fibrosis.
Cutting GR
JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
[No Abstract] [Full Text] [Related]
14. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
15. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
16. Tezacaftor for the treatment of cystic fibrosis.
Sala MA; Jain M
Expert Rev Respir Med; 2018 Sep; 12(9):725-732. PubMed ID: 30073878
[TBL] [Abstract][Full Text] [Related]
17. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.
Mall MA; Mayer-Hamblett N; Rowe SM
Am J Respir Crit Care Med; 2020 May; 201(10):1193-1208. PubMed ID: 31860331
[TBL] [Abstract][Full Text] [Related]
18. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
Solomon GM; Marshall SG; Ramsey BW; Rowe SM
Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
[TBL] [Abstract][Full Text] [Related]
19. The CF Canada-Sick Kids Program in individual CF therapy: A resource for the advancement of personalized medicine in CF.
Eckford PDW; McCormack J; Munsie L; He G; Stanojevic S; Pereira SL; Ho K; Avolio J; Bartlett C; Yang JY; Wong AP; Wellhauser L; Huan LJ; Jiang JX; Ouyang H; Du K; Klingel M; Kyriakopoulou L; Gonska T; Moraes TJ; Strug LJ; Rossant J; Ratjen F; Bear CE
J Cyst Fibros; 2019 Jan; 18(1):35-43. PubMed ID: 29685812
[TBL] [Abstract][Full Text] [Related]
20. Patient personalized translational tools in cystic fibrosis to transform data from bench to bed-side and back.
Arora K; Yang F; Brewington J; McPhail G; Cortez AR; Sundaram N; Ramananda Y; Ogden H; Helmrath M; Clancy JP; Naren AP
Am J Physiol Gastrointest Liver Physiol; 2021 Jun; 320(6):G1123-G1130. PubMed ID: 33949881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
